Equities research analysts at Zacks Research upped their Q1 2026 earnings per share estimates for Pfizer in a report released ...

Some stocks pay juicy dividends for a while only for the income to later dwindle. Others generate consistent and reliable ...

Pfizer Inc. (NYSE:PFE – Get Free Report) saw unusually large options trading activity on Thursday. Traders acquired 251,131 ...

Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Abbott also is a buy for its dividend strength. As a Dividend King it's raised its dividend for more than 50 consecutive ...

The analyst's commentary reflects careful consideration of Haleon's latest guidance and market conditions, particularly the ...

Large-cap dividend stocks will make sense as rates continue lower next year. These four have yields greater than the 10-year ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...